

MOLECULAR HAEMATOLOGY TEST REQUEST FORM



PATIENT INFORMATION		REQUESTING CLINICIAN / PATHOLOGIST		
Surname:	Sex: M / F	Name:		
First Name:	DOB:	Hospital/Lab:		
Address:		Provider No:		
		Tel: Fax:		
Medicare Number:		Referrer Signature:		
Private Health Fund: Health Fund Number:		Date:		
CLINICAL AND SAMPLE DETAILS				
Clinical Notes / Reason for Test:	(Attach a copy of relevant i	Sample Details Collection Date/Time: Bone Marrow Other (specify) Container Type (circle) EDTA / DNA / RNA / Trizol		
SELECT TEST(S)				
Diagnosis/Relapse Screening Tell FLT3-ITD, FLT3-TKD, and Note of JAK2 V617F JAK2 V617F FIP1L1::PDGFRA Myeloid NGS Panel - 52 genes - Suspected Myeloid Malignand PMF, Transplant eligible (MBS) ET/PV (MBS item 73398)	PM1 list of targets on page 2 cy (MBS item 73447)	Quantitative MRD Monitoring Tests *Please provide details of the specific mutation detected at diagnosis when sending the first sample to the lab. NPM1 IDH1 IDH2 KMT2A::X FLT3-ITD		
	ent's hospital status at the time red day hospital Patient's Signature: Health Insurance Act 1973)	Illed to the pathology provider unless otherwise specified) of the service or when the specimen was collected is required: Date: e requested pathology service(s).		
☐ Bill Hospital/Pathology Provider Direct				
☐ Bill Patient Direct (Must sign declaratio	n overleaf) 🚨 Other:			
PROVIDE THE FOLLOWING: This completed form Appropriate sample (Please see page 2 Copy of the Pathology Test Report if re		SEND TO: HMP@Alfred.org.au Alfred Pathology – Central Specimen Reception Alfred Hospital, Commercial Road, Melbourne, VIC 3004 Fax: (03) 9076 3424 Tel: (03) 9076 2383		

Your doctor recommended that you use Alfred Pathology. You are free to choose your own pathology provider. However, if your doctor has specified a particular pathologist on clinical grounds, a Medicare rebate will only be payable if that pathologist performs the service.

You should discuss this with your doctor.

Privacy Note: The information provided will be used to assess any Medicare benefit payable for the services rendered and to facilitate the proper administration of government health programs, and may be used to update enrolment records. Its collection is authorised by provision of the *Health Insurance Act 1973*. The information may be disclosed to the Department of Health and Ageing or to a person in the medical practice associated with this claim, or as authorised/required by law.

Page 1 of 2

Version 4

Test	Genes/targets covered	Price*
Myeloid NGS panel	(52 genes) GATA2, GNAS, IDH1 (exon 4, 7-9), IDH2 (exon 4, 7), JAK1 (exon 14), JAK2 (exon 1-14, 16-25), JAK3, KIT (exon 8, 11, 13-14, 17-18), KLF3, KRAS (exon 2-4), MPL, NF1, NFE2, NPM1 (exon 12), NRAS (exon 2-3), PHF6, PTPN11 (exon 3, 8, 11-13), PPM1D, RAD21, RUNX1,	
All exons in the genes		
otherwise specified	SOCS3, SRSF2 (exon 1, 2), STAG1, STAG2, STAT5B, TET2, TP53, U2AF1 (exon 2, 6) WT1 (exon 6-8), ZRSR2.	MBS73398 \$357.00
NPM1 MRD	RT-qPCR - c.860_863dup (Type A), RT-ddPCR - c.863_864insNNNN	\$196.35
IDH1 ddPCR	c.394C>T p.R132C, c.394C>G p.R132G c.394C>A p.R132S c.395G>A p.R132H, c.395G>T p.R132L	\$196.35
IDH2 ddPCR	c.419G>A p.R140Q, c.515G>A p.R172K	\$196.35
KMT2A::X RT-ddPCR	t(9;11)(p23;q23)/KMT2A::MLLT3, t(6;11)(q27;q23)/KMT2A::AFDN, t(10;11)(p12;q23)/KMT2A::MLLT10 t(11;19)(q23;p13.1)/KMT2A::ELL, t(11;19)(q23;p13.3)/KMT2A::MLLT1, t(4;11)(q21;q23)/KMT2A::AFF1	\$196.35
JAK2 ddPCR	c.1849G>T p.V617F	\$63.35
FLT3-ITD/TKD and NPM1 Fragment Analysis	ITDs in exons 14 and 15 of FLT3, TKD mutations at FLT3 codons encoding D835/I836, and insertions in the last exon of NPM1.	\$196.35
FLT3-ITD MRD NGS	ITDs in exons 14 and 15 of FLT3	\$196.35
FIP1L1::PDGFRA qPCR	All common FIP1L1::PDGFRA fusion variants	\$196.35

^{*}Claimable through Medicare if eligible: Medicare Item Numbers 73447, 73399, 73398, 73314, 73325, 73326

SAMPLE REQUIREMENTS:

DNA testing: Myeloid NGS, FLT3-ITD/TKD and	RNA testing: NPM1 MRD, KMT2A-X MRD and FIP1L1-PDGFRA
NPM1 FA, JAK2 and IDH1/2 ddPCR,	Blood and BM must be received within 48 hours of collection.
FLT3-ITD MRD NGS.	- 9ml peripheral blood (EDTA) OR
 9ml peripheral blood (EDTA) OR 	- 2-4ml of bone marrow (EDTA) OR
- 2-4ml of bone marrow (EDTA) OR	- WC pellet resuspended in Trizol
- DNA (minimum 10ul at 50ng/μl)	- RNA (minimum 10ul at 200ng/μl)

BILL PATIENT DIRECT DECLARATION: Billing of Non-Medicare Rebatable Tests

The pathology request that you have been given by your medical practitioner includes tests that could be either partially or not covered by Medicare.

If required, the full cost of testing must be covered by the patient or, in the case of children, their family. Alfred Pathology requires your consent to proceed with this testing with the full understanding that you will accept responsibility for payment.

Patient Name:
Test Name(s):
The cost of the test requested by your doctor is estimated at A\$
I hereby agree to accept responsibility for full payment or part payment of non-Medicare rebatable tests performed by Alfred Pathology.
Patient/ Parent Signature
Date// For further information, please contact Alfred Pathology on 9076 3118.